Aptevo Therapeutics Management
Management criteria checks 3/4
Aptevo Therapeutics' CEO is Marvin White, appointed in Aug 2016, has a tenure of 8.25 years. total yearly compensation is $873.45K, comprised of 64.7% salary and 35.3% bonuses, including company stock and options. directly owns 0.008% of the company’s shares, worth $408.95. The average tenure of the management team and the board of directors is 2.8 years and 8.3 years respectively.
Key information
Marvin White
Chief executive officer
US$873.4k
Total compensation
CEO salary percentage | 64.7% |
CEO tenure | 8.3yrs |
CEO ownership | 0.008% |
Management average tenure | 2.8yrs |
Board average tenure | 8.3yrs |
Recent management updates
Recent updates
Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy
Sep 19Aptevo meets primary endpoint in early-stage trial for blood cancer therapy
May 26Aptevo: Positive Early Stage Data Makes This Highly Interesting
Dec 02Aptevo gets $50/share takeout offer from shareholder Tang
Nov 18Aptevo Therapeutics rallies 113% as Tang Capital discloses 54% stake
Nov 09Aptevo sells off after clarifying complete response in early-stage study on lead drug
Nov 05CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$24m |
Jun 30 2024 | n/a | n/a | -US$25m |
Mar 31 2024 | n/a | n/a | -US$27m |
Dec 31 2023 | US$873k | US$565k | -US$19m |
Sep 30 2023 | n/a | n/a | -US$18m |
Jun 30 2023 | n/a | n/a | -US$19m |
Mar 31 2023 | n/a | n/a | US$17m |
Dec 31 2022 | US$1m | US$565k | US$7m |
Sep 30 2022 | n/a | n/a | US$6m |
Jun 30 2022 | n/a | n/a | US$6m |
Mar 31 2022 | n/a | n/a | -US$30m |
Dec 31 2021 | US$3m | US$565k | -US$29m |
Sep 30 2021 | n/a | n/a | -US$30m |
Jun 30 2021 | n/a | n/a | -US$30m |
Mar 31 2021 | n/a | n/a | -US$29m |
Dec 31 2020 | US$971k | US$498k | -US$31m |
Sep 30 2020 | n/a | n/a | -US$33m |
Jun 30 2020 | n/a | n/a | -US$37m |
Mar 31 2020 | n/a | n/a | -US$41m |
Dec 31 2019 | US$974k | US$547k | -US$43m |
Sep 30 2019 | n/a | n/a | -US$48m |
Jun 30 2019 | n/a | n/a | -US$49m |
Mar 31 2019 | n/a | n/a | -US$52m |
Dec 31 2018 | US$1m | US$565k | -US$54m |
Sep 30 2018 | n/a | n/a | -US$49m |
Jun 30 2018 | n/a | n/a | -US$34m |
Mar 31 2018 | n/a | n/a | -US$35m |
Dec 31 2017 | US$1m | US$543k | -US$33m |
Compensation vs Market: Marvin's total compensation ($USD873.45K) is above average for companies of similar size in the US market ($USD652.28K).
Compensation vs Earnings: Marvin's compensation has been consistent with company performance over the past year.
CEO
Marvin White (62 yo)
8.3yrs
Tenure
US$873,446
Compensation
Mr. Marvin L. White has been an Independent Director at Emergent BioSolutions Inc. since 2022 and served as its Director since October 1, 2020 until 2022. Mr. White has been the Chief Executive Officer, Pr...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 8.3yrs | US$873.45k | 0.0083% $ 409.0 | |
Executive VP & COO | 1.7yrs | US$741.59k | 0.0063% $ 311.2 | |
Senior VP | 3.3yrs | US$654.73k | 0.0043% $ 213.9 | |
Senior VP & CFO | 1.7yrs | no data | 0.0031% $ 153.6 | |
Chief Medical Officer | 2.8yrs | no data | no data |
2.8yrs
Average Tenure
58yo
Average Age
Experienced Management: APVO's management team is considered experienced (2.8 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 8.3yrs | US$873.45k | 0.0083% $ 409.0 | |
Independent Director | 8.3yrs | US$73.21k | 0.0015% $ 74.1 | |
Independent Director | 8.3yrs | US$93.21k | 0.0015% $ 74.6 | |
Independent Chairman | 8.3yrs | US$88.21k | 0.0012% $ 57.8 | |
Independent Director | 8.3yrs | US$78.21k | 0.0011% $ 52.8 | |
Independent Director | 8.3yrs | US$70.71k | 0.0011% $ 52.8 |
8.3yrs
Average Tenure
68.5yo
Average Age
Experienced Board: APVO's board of directors are considered experienced (8.3 years average tenure).